Allozyne
Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.
Launch date
Employees
Market cap
-
Enterprise valuation
$6m (Public information from Sep 2014)
Seattle Washington (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$3.5m | Series A | ||
$30.0m | Series B | ||
| N/A | $2.5m | Debt | |
| N/A | $900k | Debt | |
$5.5m Valuation: $5.5m | Acquisition | ||
| Total Funding | $33.5m | ||
Related Content
Recent News about Allozyne
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.